Moon Surgical’s Maestro Robotic Laparoscopy Platform Receives FDA Clearance for Commercial Use

1. FDA Clearance: Moon Surgical's Maestro robotic laparoscopy platform has received commercial clearance from the US Food and Drug Administration (FDA).
2. Commercial Launch: The company plans to launch the Maestro System commercially, following a successful European rollout and the treatment of over 200 patients to date.
3. System Capabilities: The Maestro System enhances operating room efficiency, enables alternative labor models, and ensures shorter, more predictable procedure durations. It also features real-time AI algorithms using NVIDIA Holoscan.
4. Market Potential: The system is designed to support the 18.8 million annual soft tissue surgical procedures not currently addressed by existing telerobotic systems.
5. Company Background: Moon Surgical is a French-American company founded in 2020, known for its commitment to innovation and fostering a diverse, creative, and collaborative team environment.